that might be the only thing that would make this POS stock go up and stay up!!! Very frustrating to buy and hold!!!
if it works, the path would be rapid since the drug is already approved. Also, it would be prescribed off label rapidly. If it works, we shall see. Since side effects are much lower than Chantix, it just has to work almost as well. It's easy to use Google and find out about phase III results for the approved products.
yes agree, this new report was old, recycled opinions from a paid bear at a new firm, a non-event. They pricked the overbought bubble, but IMGN is greatly under-valued and one day soon I may make it my mission to help the IMGN shareholders get full value. Dear Mr. Icahn...trading at $12, worth $20+ how much would you like to buy?
EXEL was doomed when they foolishly made a deal with the Devil / Financial bio-mob DF. I never invest with DF, they wrang every nickel out of ARNA before management finally bought them off.
This BS is really getting annoying, DJ and the BOD all need to go. One day soon, I will make it my FT job to find an activist to force the BOD to take action to remove DJ and sell to the highest bidder. The IMGN shareholders deserve better!
good info, thanks. It's not difficult to manipulate this stock since it's news driven. IMGN IR is terrible, CEO has lost credibility, shareholder faith rests in John Lambert and co. This is probably a good trading entry spot IMO.
Analyst says no catalyst, $6BB peak Kadcyla sales, no terminal value, assigns $0 to the pipeline and not much for the partnerships. The report is BS and the execs need to go for failing to max shareholder value!
Price target $10 lovely hit piece by the MS criminals. Also, nice work by DJ and company. As always, shareholders are the losers. If anyone can find their central thesis, please let me know.
that's a good question for IR, but they will probably refer you to a filing. I am sure it's better than Kadcyla, probably not as strong as the most recent deals. With 3 compounds now in the clinic and 2 more in pre-clinical, Sanofi is becoming the most interesting partner.
yes, this is encouraging. The only thing that causes doubt is the heavy insider selling. Tell them to knock it off!
yes, I think you may have found something, there seem to be more undisclosed and a third Sanoif with a name and number. It's a big pipeline (although early stage) for a $1BB company with a proven blockbuster already on the market. Management needs to pick up the pace, or find a way to monetize value for the long suffering shareholders!
the other + side is valuation. If Mersana can sign one deal worth $792, it's obvious that the sum of IMGN's parts are worth far more than the current valuation, at least $2BB IMO. Without a catalyst, activist, etc. we must wait it seems.
Looks like IMGN lost out on another significant Bus Dev opportunity. What are the 3-4 BD people that IMGN employs doing?
they develop some antibodies, they developed the one used for 289 and the other internal programs I believe. Not sure why they did not add conjugation to the Sanofi molecule.
I don't understand how shorts are exiting while share price is going down. If ARNA's IR and Exec team could generate any institutional buying, they would not be able to cover so easily. The medical evidence seems positive, but it's not translating into pps. Very frustrating, but I remain long and impatient.
While this sounds impressive and positive, we (shareholders) are all waiting for this positive news to be reflected in the stock price. That's the ONLY thing I care about and it's not going well for the shareholders. I seem to be the only shareholder that cares about the excesses of the BOD and execs. Do people really think Directors are earning their $150K. How much time and effort are they investing for that pay? How much value are they adding?